🎯 Today's Pharma Pulse
Oral KRAS inhibitor daraxonrasib doubles survival in pancreatic cancer trial
A phase III trial of the oral KRAS inhibitor daraxonrasib reported a median overall survival of 13.2 months for patients with metastatic pancreatic ductal adenocarcinoma, roughly twice the 6.6 months seen with standard chemotherapy. The study enrolled 500 participants and noted fewer side‑effects compared with conventional regimens. Results were presented at the ASCO meeting in Chicago.
💬 Top Pharma Social Posts
Tweet by @Bradloncar
This is a historic data release. A real advance for pancreatic cancer patients, and it shows that our industry goes after the hardest things and can win. #ASCO26 https://t.co/w6F1yAkwK0
Thread by @Periodtrader
Vir’s tobevibart + elebsiran hit 65.9% undetectable HDV RNA at week 24 in the SOLSTICE trial. Big step toward a potential accelerated approval for hepatitis D. HepatitisD